Publication: Malignant ascites in female patients : A seven-year review
Issued Date
1999-01-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0032605536
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.82, No.1 (1999), 15-19
Suggested Citation
Sarikapan Wilailak, Vasant Linasmita, Songsri Srivannaboon Malignant ascites in female patients : A seven-year review. Journal of the Medical Association of Thailand. Vol.82, No.1 (1999), 15-19. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25717
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Malignant ascites in female patients : A seven-year review
Other Contributor(s)
Abstract
Malignant ascites is common in various types of advanced cancer. Our objective was to determine the primary site and the clinical characteristics of female patients presenting with malignant ascites as well as evaluating the outcome. The authors carried out a retrospective study of 118 cases of malignant ascites diagnosed from January 1986 to December 1992 in female patients. Of the 118 cases, the primary site of the neoplasms was gynecologic in 65 cases (cervix 4, endometrium 6, ovary 52, fallopian tube 3) = 55.1 per cent, non-gynecologic 29 cases (GI 18, lymphoma 8, breast 2, kidney 1) = 24.6 per cent, and unknown 24 cases = 20.3 per cent. The mean age of patients in the gynecologic, non-gynecologic and unknown primary site was 50.4, 45.5 and 59.3 years respectively. Surgery combined with chemotherapy was the main treatment in the gynecologic group, whereas, supportive and symptomatic management was the main treatment in the unknown primary group. Treatments in non-gynecologic group were supportive and symptomatic, surgery and chemotherapy. Survival was longer in gynecologic than in the non-gynecologic and the unknown primary groups. The most common primary site of malignant ascites in females was ovarian cancer. In malignant ascites in females caused by gynecologic neoplasms, the prognosis as measured by survival was better than in the non-gynecologic and the unknown primary groups.